Merck Highlights Results from Various P-III Trials of V116 Vaccine for Pneumococcal Diseases at ISPPD-13 2024
Shots:
- The P-III studies assessed the safety & immunogenicity of V116 across STRIDE-3 in pneumococcal vaccine-naïve adults, STRIDE-6 in pneumococcal vaccine-experienced adults, STRIDE-7 in HIV adults, STRIDE-9 in vaccine-naïve Japanese adults & PNEUMO trial in community-acquired pneumonia patients
- The results, at D30, depicted V116’s immunogenicity in vaccine-naïve adults (50yrs. & above) for all 21 serotypes. A comparable immune response for shared serotypes with PCV15 or PPSV23 & a higher immune response for serotypes unique to V116 was seen in vaccine-experienced adults (50yrs. & above)
- A comparable immune response for all 13 shared serotypes with PCV15 + PPSV23 & a higher immune response unique to V116 for 8 serotypes was seen in HIV adults (18yrs. & above) at D30
Ref: Merck | Image: Merck
Related News:- The US FDA Accepts Merck’s BLA for V116 and Grants Priority Review for the Prevention of Pneumococcal Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
